

Current primary open-angle glaucoma treatments and

Clinical Ophthalmology

6, 1699

DOI: [10.2147/opth.s32933](https://doi.org/10.2147/opth.s32933)

Citation Report

#	ARTICLE	IF	CITATIONS
1	New Therapeutic Targets for Intraocular Pressure Lowering. <i>ISRN Ophthalmology</i> , 2013, 2013, 1-14.	1.7	31
2	Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews. <i>Croatian Medical Journal</i> , 2014, 55, 468-480.	0.7	15
3	Bimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical setting. <i>BMC Ophthalmology</i> , 2014, 14, 160.	1.4	8
4	Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy. <i>Clinical Ophthalmology</i> , 2015, 9, 825.	1.8	9
5	Novel Potential Treatment Modalities for Ocular Hypertension: Focus on Angiotensin and Bradykinin System Axes. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2015, 31, 131-145.	1.4	13
6	Retinal ganglion cell neuroprotection induced by activation of alpha7 nicotinic acetylcholine receptors. <i>Neuropharmacology</i> , 2015, 99, 337-346.	4.1	27
7	Intraocular pressure control in patients with primary open angle glaucoma and diabetes mellitus. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2016, 91, 125-129.	0.2	0
8	Synthesis and <i>In Vitro</i> Pharmacological Evaluation of 5-(Alkoxyethyl)-3-(alkylamino)hydroxypropoxyphenylethanones Related to Acebutolol and Celiprolol. <i>Archiv Der Pharmazie</i> , 2016, 349, 733-740.	4.1	2
9	Glaucoma-inducing Procedure in an <i>In Vivo</i> Rat Model and Whole-mount Retina Preparation. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	4
10	Building a glaucoma interaction network using a text mining approach. <i>BioData Mining</i> , 2016, 9, 17.	4.0	4
11	Inter-device reproducibility of retrobulbar blood flow velocity measurements in healthy subjects using color Doppler imaging. <i>Journal of Ultrasound</i> , 2016, 19, 125-130.	1.3	3
12	Control de la presión intraocular en pacientes con glaucoma primario de ángulo abierto y diabetes mellitus. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2016, 91, 125-129.	0.2	0
13	Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 788-809.	6.4	55
14	Evidence of BrdU-positive retinal neurons after application of an Alpha7 nicotinic acetylcholine receptor agonist. <i>Neuroscience</i> , 2017, 346, 437-446.	2.3	16
15	Characterizing the "POAGome": A bioinformatics-driven approach to primary open-angle glaucoma. <i>Progress in Retinal and Eye Research</i> , 2017, 58, 89-114.	15.5	57
16	Open-angle glaucoma: therapeutically targeting the extracellular matrix of the conventional outflow pathway. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 1037-1050.	3.4	41
17	Collagen and chondroitin sulfate scaffolds with uniaxially aligned pores for the biomimetic, three dimensional culture of trabecular meshwork cells. <i>Biotechnology and Bioengineering</i> , 2017, 114, 915-923.	3.3	35
18	Correlations of AFAP1, GMDS and PTGFR gene polymorphisms with intra-ocular pressure response to latanoprost in patients with primary open-angle glaucoma. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 87-92.	1.5	12

#	ARTICLE	IF	CITATIONS
20	Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma. <i>Small</i> , 2018, 14, 1701808.	10.0	77
21	Effect of myricetin on primary open-angle glaucoma. <i>Translational Neuroscience</i> , 2018, 9, 132-141.	1.4	16
22	Cost-effectiveness analysis of iStent trabecular micro-bypass stent for patients with open-angle glaucoma in Colombia. <i>Current Medical Research and Opinion</i> , 2019, 35, 329-340.	1.9	19
23	Meibomian gland dropout rate as a method to assess meibomian gland morphologic changes during use of preservative-containing or preservative-free topical prostaglandin analogues. <i>PLoS ONE</i> , 2019, 14, e0218886.	2.5	12
24	Semi-permanent transcorneal filter support and in vivo surgical implantation technique for open-angle glaucoma treatment. <i>Biomedical Microdevices</i> , 2019, 21, 92.	2.8	0
25	Once Daily Pregabalin Eye Drops for Management of Glaucoma. <i>ACS Nano</i> , 2019, 13, 13728-13744.	14.6	27
26	Possible role of differentially expressing novel protein markers (ligatin and fibulin-7) in human aqueous humor and trabecular meshwork tissue in glaucoma progression. <i>Cell Biology International</i> , 2019, 43, 820-834.	3.0	4
27	Stimulation of Retinal Pigment Epithelium With an $\alpha 7$ nAChR Agonist Leads to Müller Glia Dependent Neurogenesis in the Adult Mammalian Retina. , 2019, 60, 570.		14
28	Waveform parameters of retrobulbar vessels in glaucoma patients with different demographics and disease severity. <i>European Journal of Ophthalmology</i> , 2020, 30, 1019-1027.	1.3	4
29	Extracellular Vesicles Mediate Anti-Oxidative Response- In Vitro Study in the Ocular Drainage System. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6105.	4.1	24
30	Molecular Genetics and Functional Analysis Implicate CDKN2BAS1-CDKN2B Involvement in POAG Pathogenesis. <i>Cells</i> , 2020, 9, 1934.	4.1	13
31	The Pro-Fibrotic Behavior of Human Tenon's Capsule Fibroblasts in Medically Treated Glaucoma Patients. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 1391-1402.	1.8	11
32	Human trabecular meshwork cell behavior is influenced by collagen scaffold pore architecture and glycosaminoglycan composition. <i>Biotechnology and Bioengineering</i> , 2020, 117, 3150-3159.	3.3	26
33	TGF- $\beta 2$ Promotes Oxidative Stress in Human Trabecular Meshwork Cells by Selectively Enhancing NADPH Oxidase 4 Expression. , 2021, 62, 4.		15
34	Effect of Jyoti-Trataka on intraocular pressure, autonomic control, and blood glucose in diabetic patients with high-tension primary open-angle glaucoma: a randomized-controlled trial. <i>Journal of Complementary and Integrative Medicine</i> , 2022, 19, 1013-1018.	0.9	9
35	In Silico Screening and In Vivo Evaluation of Potential CACNA2D1 Antagonists as Intraocular Pressure-Reducing Agents in Glaucoma Therapy. <i>Pharmaceuticals</i> , 2021, 14, 887.	3.8	6
36	SARM1 acts downstream of neuroinflammatory and necroptotic signaling to induce axon degeneration. <i>Journal of Cell Biology</i> , 2020, 219, .	5.2	99
37	Efficacy and Tolerability of the Fixed Combinations Latanoprost/Timolol versus Dorzolamide/Timolol in Patients with Elevated Intraocular Pressure: A Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2013, 8, e83606.	2.5	6

#	ARTICLE	IF	CITATIONS
38	Present and New Treatment Strategies in the Management of Glaucoma. Open Ophthalmology Journal, 2015, 9, 89-100.	0.2	37
39	Under pressure: a review of normal-tension glaucoma. Canadian Journal of Optometry, 2012, 74, 33.	0.0	1
42	Glaucomatous optic neuropathy management: the role of neuroprotective agents. Medical Hypothesis, Discovery, and Innovation in Ophthalmology, 2013, 2, 41-6.	0.2	10
43	A Review on Newer Ocular Drug Delivery Systems with an Emphasis on Glaucoma. Advanced Pharmaceutical Bulletin, 2021, 11, 399-413.	1.4	0
44	Photoinduced Gelatin-Methacrylate Scaffolds to Examine the Impact of Extracellular Environment on Trabecular Meshwork Cells. Industrial & Engineering Chemistry Research, 0, , .	3.7	4
45	Parylene-C Microbore Tubing: A Simpler Shunt for Reducing Intraocular Pressure. IEEE Transactions on Biomedical Engineering, 2022, 69, 1264-1272.	4.2	1
46	A Review on Newer Ocular Drug Delivery Systems with an Emphasis on Glaucoma. Advanced Pharmaceutical Bulletin, 2020, 11, 399-413.	1.4	4
47	Vitamin intake and glaucoma risk: A systematic review and meta-analysis. Journal Francais D'Ophthalmologie, 2022, 45, 519-528.	0.4	7
48	Micropulse laser trabeculoplasty and reduction of intraocular pressure: A preliminary study. Saudi Journal of Ophthalmology, 2021, 35, 122.	0.3	0
49	Intravitreal <i>Trans-</i>Resveratrol Ameliorates NMDA-Induced Optic Nerve and Retinal Injury. Current Eye Research, 2022, 47, 866-873.	1.5	3
50	Efficacy of Nimodipine Combined with Latanoprost in Treating Open-Angle Glaucoma and Its Influence on Ocular Hemodynamics and Visual Field Defects. Drug Design, Development and Therapy, 2022, Volume 16, 749-757.	4.3	3
51	Associations of statin use with the onset and progression of open-angle glaucoma: A systematic review and meta-analysis. EClinicalMedicine, 2022, 46, 101364.	7.1	8
52	Outcomes of initial and repeat micro-pulse transscleral cyclophotocoagulation in adult glaucoma patients. Therapeutic Advances in Ophthalmology, 2022, 14, 251584142110644.	1.4	3
54	Effects of Netarsudil-Family Rho Kinase Inhibitors on Human Trabecular Meshwork Cell Contractility and Actin Remodeling Using a Bioengineered ECM Hydrogel. Frontiers in Ophthalmology, 0, 2, .	0.5	5
55	The role of Vitamin D3 in ocular fibrosis and its therapeutic potential for the glaucomatous trabecular meshwork. Frontiers in Ophthalmology, 0, 2, .	0.5	0
56	Analysis of aerobic exercise influence on intraocular pressure and ocular perfusion pressure in patients with primary open-angle glaucoma: A randomized clinical trial. Indian Journal of Ophthalmology, 2022, 70, 4228-4234.	1.1	3
57	The potential for mitochondrial therapeutics in the treatment of primary open-angle glaucoma: a review. Frontiers in Physiology, 0, 14, .	2.8	4
58	Effect of Selective Laser Trabeculoplasty on the Fellow Eye. Journal of Current Glaucoma Practice, 2024, 17, 175-177.	0.5	0